- Prohealth - https://www.prohealth.com -

Randomised, double-blind, placebo-controlled study of pivagabine in NA

One hundred and eighteen patients with neurasthenia, as
defined by ICD 10 (International Classification of Diseases),
participated in a randomised, double-blind, placebo-controlled
trial of pivagabine (4-[(2,2-dimethyl-1-oxopropyl)amino]butanoi
d, CAS 69542-93-4, Tonerg). Pivagabine 1800 mg/d was
administered orally for four weeks. At the end of the trial,
active medication was significantly superior to placebo on the
Clinical Global Impression (CGI) improvement of illness scale.
In addition, pivagabine treatment reduced the physical and
mental fatigability of patients, and increased their sense of